| Prev Close | 112.47 |
| Day Low/High | 109.72 / 113.79 |
| 52 Wk Low/High | 92.56 / 141.86 |
| Avg Volume | 1.78M |
Alexion Pharmaceuticals Inc. (ALXN)
110.42
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 221.29M |
| Market Cap | 24.89B |
| EPS | 0.30 |
| P/E Ratio | 7.77 |
| Div & Yield | N.A. (N.A) |
Sitting Tight for Respectable Volume
The light volume keeps me hesitant, though here are a few recent standout names.
Bull Market in Biotech
The biotechnology sector has weathered the correction and looks ready to push higher.
Fitz Bits: More Quick Bites
Here's another serving of buy-on-the-bounce trades
Mo-Mos Lose Their Mojo
Momentum stocks are under fairly severe pressure.
The Week Ahead: Housing Data, GDP and Earnings
Contributor Ken Shreve takes a look at economic data and earnings reports scheduled for the coming week.
Not for the Faint of Heart
The high-fliers I have been showing can reap huge returns, but make sure you can handle the volatility.
Fitz Bits: Stay Long Alexion
The shares are highly likely to test $100. Just keep a trailing stop on any existing positions.
Look for Resting Stocks
The virtuous cycle of overrunning price targets is in effect.
The Cure for Alexion
With only one drug on the market, the pharmaceutical company is expanding its pipeline.
The Day Ahead: Pulling Back
News that Greece will need further austerity measures dragged down world markets and U.S. futures.
The Day Ahead: Positioning for 'Jobs Friday'
Stocks were poised for a moderately higher ahead of this highly anticipated monthly event.
Squinting for Playable Stocks
Despite the massive upsurge, there are still a few interesting setups to consider here.
Searching for a Pulse
It's not that the market action is bad, it just isn't lively enough to support aggressive action.
Scrutinize Those Breakouts
Some breakouts, like that of Apple lately, cannot be taken at face value -- especially if they lack volume.
Strong Volume Equals a Strong Foundation
EBIX broke out on Tuesday in heavy volume, which hints at institutional buying in this stock.
Off the Charts
Keep your risk down at this point as the market still has a lot to prove.
More Safe-Haven Ideas
Consider this strategy to help protect your portfolio as what could be a very treacherous earnings season approaches.
Biotech Is Booming
Despite the solid performance so far this year, there's still time to get on board and ride the profit train.
Big-Cap Momentum Names Still Hold Sway
Money is still flowing into some market-moving names, but not into small-caps.
Fitz Bits: This Calls for Patience
Alexion Pharma is too far above established support to be considered a buy at this point, so wait for a pullback closer to this key level.
Three Rock-Solid Names to Watch
If institutional buyers come into these stocks soon, we could have a nice year-end rally on our hands.
Don't Stay Married to Former Leaders
Focus on stocks that have come in no more than 30% off their recent highs as they have a good chance of forming sound bases and staging new breakouts.
